Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ustekinumab or golimumab versus placebo in chronic sarcoidosis
NL-OMON36553Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in sarcoidosis, pulmonary sarcoidosis and cutaneous sarcoidosis comparing Ustekinumab, Golimumab and Placebo (3 arms). Primary endpoint: Primary endpoint not reported in registry entry. Started May 2010; status: active, not recruiting.
02
Drugs
ustekinumabgolimumab
03
Conditions
sarcoidosispulmonary sarcoidosiscutaneous sarcoidosis
Beyond the preview
Go deeper on NL-OMON36553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36553.